Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

(2012) Ensio Norjavaara et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

(2012) Michael J. Waring et al.   MedChemComm

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

(2010) G. Schernthaner et al.   DIABETOLOGIA

Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study

(2010) Riccardo C. Bonadonna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Estimating glomerular filtration rate

(2009) W. Greg Miller   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment

(2009) A. Giaccari et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Targeting Hepatic Glucokinase in Type 2 Diabetes: Weighing the Benefits and Risks

(2008) L. Agius   DIABETES

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor

(2008) R. Murphy et al.   DIABETOLOGIA

New Drugs for Type 2 Diabetes Mellitus

(2008) Andrew J Krentz et al.   DRUGS

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS